Fatima Al-Shahrour
Overview
Explore the profile of Fatima Al-Shahrour including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
114
Citations
5418
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rogado J, Pozo F, Troule K, Pacheco M, Adrados M, Sanchez-Torres J, et al.
Clin Transl Oncol
. 2024 Dec;
PMID: 39708256
Introduction: Peripheral blood mononuclear cells (PBMCs) trafficking is regulated by chemokines, which modulate leukocyte migration toward tumors and may collaborate in the efficacy of immunotherapy. In our study, we investigated...
2.
Jimenez-Santos M, Garcia-Martin S, Rubio-Fernandez M, Gomez-Lopez G, Al-Shahrour F
NAR Cancer
. 2024 Dec;
6(4):zcae046.
PMID: 39703753
Breast cancer patients are categorized into three subtypes with distinct treatment approaches. Precision oncology has increased patient outcomes by targeting the specific molecular alterations of tumours, yet challenges remain. Treatment...
3.
Priego N, de Pablos-Aragoneses A, Perea-Garcia M, Pieri V, Hernandez-Oliver C, Alvaro-Espinosa L, et al.
Cancer Discov
. 2024 Oct;
15(1):179-201.
PMID: 39354883
Immunotherapies against brain metastases have shown clinical benefits when applied to asymptomatic patients, but they are largely ineffective in symptomatic cases for unknown reasons. Here, we dissect the heterogeneity in...
4.
Monteagudo M, Calsina B, Salazar-Hidalgo M, Martinez-Montes A, Pineiro-Yanez E, Caleiras E, et al.
Best Pract Res Clin Endocrinol Metab
. 2024 Sep;
38(6):101931.
PMID: 39218714
Pheochromocytomas and paragangliomas are rare neuroendocrine tumours. Around 20-25 % of patients develop metastases, for which there is an urgent need of prognostic markers and therapeutic stratification strategies. The presence...
5.
Type I interferon signaling pathway enhances immune-checkpoint inhibition in KRAS mutant lung tumors
Fernandez-Garcia F, Fernandez-Rodriguez A, Fustero-Torre C, Pineiro-Yanez E, Wang H, Lechuga C, et al.
Proc Natl Acad Sci U S A
. 2024 Aug;
121(36):e2402913121.
PMID: 39186651
Lung cancer is the leading cause of cancer mortality worldwide. KRAS oncogenes are responsible for at least a quarter of lung adenocarcinomas, the main subtype of lung cancer. After four...
6.
Riba M, Sala C, Culhane A, Flobak A, Patocs A, Boye K, et al.
Nat Genet
. 2024 May;
56(5):733-736.
PMID: 38702538
No abstract available.
7.
Nikolski M, Hovig E, Al-Shahrour F, Blomberg N, Scollen S, Valencia A, et al.
Nat Cancer
. 2024 Feb;
5(3):367-372.
PMID: 38321342
No abstract available.
8.
Chaib S, Lopez-Dominguez J, Lalinde-Gutierrez M, Prats N, Marin I, Boix O, et al.
Nat Cancer
. 2024 Jan;
5(3):448-462.
PMID: 38267628
Chemotherapy often generates intratumoral senescent cancer cells that strongly modify the tumor microenvironment, favoring immunosuppression and tumor growth. We discovered, through an unbiased proteomics screen, that the immune checkpoint inhibitor...
9.
Sanchez-Aguilera A, Masmudi-Martin M, Navas-Olive A, Baena P, Hernandez-Oliver C, Priego N, et al.
Cancer Cell
. 2023 Aug;
41(9):1637-1649.e11.
PMID: 37652007
A high percentage of patients with brain metastases frequently develop neurocognitive symptoms; however, understanding how brain metastasis co-opts the function of neuronal circuits beyond a tumor mass effect remains unknown....
10.
Sanchez-Sanz A, Garcia-Martin S, Sabin-Munoz J, Moreno-Torres I, Elvira V, Al-Shahrour F, et al.
Front Immunol
. 2023 Jul;
14:1209923.
PMID: 37483622
Background And Objective: Dimethyl fumarate (DMF) is an immunomodulatory drug approved for the therapy of multiple sclerosis (MS). The identification of response biomarkers to DMF is a necessity in the...